Open House Rebate Agreement for Interferon beta-1a (Avonex)
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Avonex(R), ATC L03AB07
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
10 / 100
Risk factors
The open-house agreement may be automatically displaced by any subsequent nationwide or regional rebate contract for th...
The buyer may terminate the agreement with one month's notice without cause.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Non-exclusive rebate agreements for Interferon beta-1a (Avonex(R)), ATC L03AB07, under § 130a Abs. 8 SGB V.
- Contracts are identical and not individually negotiable.
Show full summary
This is an open-house (non-competitive) procedure by AOK Bayern for non-exclusive rebate agreements on the pharmaceutical product Interferon beta-1a (Avonex(R)), ATC L03AB07. Any eligible pharmaceutical company can join under identical, non-negotiable terms. Contracts run from 01.06.2026 to 31.05.2028, with the possibility to sign at any time until 03.04.2028. The procedure is not subject to procurement law; no award criteria apply. Only a signed self-declaration of reliability is required for eligibility. Documents must be submitted in German, either in paper (two original copies) or electronically with a qualified electronic signature. No estimated contract value is provided. Risks include automatic termination if superseded by another rebate contract and the possibility of cancellation with one month's notice.
Risks
The open-house agreement may be automatically displaced by any subsequent nationwide or regional rebate contract for th...
The buyer may terminate the agreement with one month's notice without cause.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible.
Certifications
- Documents must be in German; non-German documents require a certified translation.
Administrative
- Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Rebate Agreement for Interferon beta-1a (Avonex)
Non-exclusive rebate agreement for Interferon beta-1a (Avonex(R)), ATC L03AB07. Open to all eligible pharmaceutical companies. Contract period 01.06.2026 – 31.05.2028. No award criteria; all eligible participants receive a contract.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Avonex(R), ATC L03AB07
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 254339-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
10 / 100
Risk factors
The open-house agreement may be automatically displaced by any subsequent nationwide or regional rebate contract for th...
The buyer may terminate the agreement with one month's notice without cause.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications